Association of osteopontin polymorphisms with nasopharyngeal carcinoma risk

Human Immunology

Volumn 75, Issue 1, 2014, Pages 76-80

  Wang, Junli ^a   Nong, Legen ^a   Wei, Yesheng ^a   Qin, Shanyu ^b   Zhou, You ^c   Tang, Yujin ^a  

^a YOUJIANG MEDICAL COLLEGE FOR NATIONALITIES   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^c MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISTANT METASTASIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; CASE-CONTROL STUDIES; ERYTHROMYCIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; OSTEOPONTIN; POLYMORPHISM, GENETIC;

EID: 84890190845     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.09.014     Document Type: Article

References (29)

1. Wei K.R., Yu Y.L., Yang Y.Y., Ji M.F., Yu B.H., Liang Z.H., et al. Epidemiological trends of nasopharyngeal carcinoma in China. Asian Pac J Cancer Prev 2010, 11:29.
2. Zhou G., Zhai Y., Cui Y., Zhang X., Dong X., Yang H., et al. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 2007, 13:2627.
3. Li Y., Fu L., Wong A.M., Fan Y.H., Li M.X., Bei J.X., et al. Identification of genes with allelic imbalance on 6p associated with nasopharyngeal carcinoma in southern Chinese. PLoS One 2011, 6:e14562.
4. Cho W.C. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007, 6:1.
5. Zhang R., Pan X., Huang Z., Weber G.F., Zhang G. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One 2011, 6:e23831.
6. Zhao X.Q., Dong J.H., Zhang W.Z., Liu Z. Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin. Diagn Pathol 2011, 6:98.
7. Young M.F., Kerr J.M., Termine J.D., Wewer U.M., Wang M.G., McBride O.W., et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990, 7:491.
8. Giacopelli F., Marciano R., Pistorio A., Catarsi P., Canini S., Karsenty G., et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004, 20:87.
9. Hull J., Campino S., Rowlands K., Chan M.S., Copley R.R., Taylor M.S., et al. Identification of common genetic variation that modulates alternative splicing. PLoS Genet 2007, 3:e99.
10. Chen Y., Liu H., Wu W., Li Y., Li J. Osteopontin genetic variants are associated with overall survival in advanced non-small cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res 2013, 32:45.
11. Dong Q.Z., Zhang X.F., Zhao Y., Jia H.L., Zhou H.J., Dai C., et al. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology 2013, 57:1024.
12. Zhao F., Chen X., Meng T., Hao B., Zhang Z., Zhang G. Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer 2012, 12:477.
13. Xu Q., Yuan B., Xue F., Zhang L., Li J., Guo H., et al. OPN gene polymorphisms are associated with susceptibility and clinicopatholigical characteristics of cervical cancer in a Chinese cohort. Cancer Biomark 2011, 10:233.
14. Jiang S., Chen X., Li C., Zhang X., Zhang T., Yue Y., et al. Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin. Mol Med Rep 2012, 6:1351.
15. Wang H.H., Wang X.W., Tang C.E. Osteopontin expression in nasopharyngeal carcinoma: its relevance to the clinical stage of the disease. J Cancer Res Ther 2011, 7:138.
16. Arjomandi M., Galanter J.M., Choudhry S., Eng C., Hu D., Beckman K., et al. Polymorphism in osteopontin gene (SPP1) is associated with asthma and related phenotypes in a Puerto Rican population. Pediatr Allergy Immunol Pulmonol 2011, 24:207.
17. Glas J., Seiderer J., Bayrle C., Wetzke M., Fries C., Tillack C., et al. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease. PLoS One 2011, 6:e29309.
18. Chu M., Yang P., Hou S., Li F., Chen Y., Kijlstra A. Behcet's disease exhibits an increased osteopontin serum level in active stage but no association with osteopontin and its receptor gene polymorphisms. Hum Immunol 2011, 72:525.
19. Safarinejad M.R., Shafiei N., Safarinejad S. Association between polymorphisms in osteopontin gene (SPP1) and first episode calcium oxalate urolithiasis. Urolithiasis 2013, 41:303.
20. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978.
21. Bellahcene A., Castronovo V., Ogbureke K.U., Fisher L.W., Fedarko N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008, 8:212.
22. Hui E.P., Sung F.L., Yu B.K., Wong C.S., Ma B.B., Lin X., et al. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res 2008, 14:7080.
23. Wong T.S., Kwong D.L., Sham J., Wei W.I., Kwong Y.L., Yuen A.P. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 2005, 31:555.
24. Papworth K., Bergh A., Grankvist K., Ljungberg B., Sandlund J., Rasmuson T. Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma. Acta Oncol 2013, 52:159.
25. Liersch R., Gerss J., Schliemann C., Bayer M., Schwoppe C., Biermann C., et al. Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood 2012, 119:5215.
26. Mu G., Wang H., Cai Z., Ji H. OPN -443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese Cohort. Cell Physiol Biochem 2013, 32:171.
27. Chang Y.S., Kim H.J., Chang J., Ahn C.M., Kim S.K. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007, 57:373.
28. Chen J., Wu Q., Lu Y., Xu T., Huang Y., Ribas J., et al. SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J Hum Genet 2010, 55:456.
29. Chu M., Yang P., Hu R., Hou S., Li F., Chen Y., et al. Elevated serum osteopontin levels and genetic polymorphisms of osteopontin are associated with Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 2011, 52:7084.